Table 2. Univariate for OS and DFS in 124 cases of ICC after resection.

Variables	n	Overall survival				Disease-free survival
		HR	95% CI	P		HR	95% CI	P
Gender (male)	68	2.23	1.22–4.10	0.010*		1.22	0.79–1.88	0.364
Age ≥60	69	1.14	0.65–2.00	0.659		0.79	0.52–1.22	0.286
Multiple tumors	31	2.64	1.48–4.70	0.001*		2.23	1.40–3.53	0.001*
Largest diameter >5 cm	59	2.47	1.37–4.45	0.003*		1.94	1.26–2.99	0.003*
Incomplete tumor capsule	10	0.84	0.30–2.33	0.731		0.87	0.40–1.88	0.718
Visceral peritoneal perforation	11	4.75	2.19–10.33	<0.001*		3.40	1.77–6.55	<0.001*
Vascular invasion	26	1.95	1.03–3.69	0.040*		1.99	1.21–3.28	0.007*
Lymph node metastasis	18	3.08	1.54–6.18	0.002*		3.54	2.04–6.13	<0.001*
Edmondson grades III/IV	82	1.54	0.83–2.86	0.166		1.42	0.89–2.27	0.141
Liver cirrhosis	28	0.88	0.45–1.70	0.704		0.83	0.49–1.39	0.473
Child-Pugh B or C	2	0.42	0.10–1.77	0.239		0.84	0.21–3.43	0.806
HBsAg positive	44	0.89	0.49–1.61	0.696		1.01	0.65–1.58	0.958
TB >20.4 U/L	8	2.59	1.09–6.11	0.030*		1.14	0.50–2.62	0.760
ALB ≥35 g/L	116	0.73	0.26–2.05	0.554		0.85	0.39–1.84	0.674
ALT >40 U/L	19	1.65	0.86–3.16	0.135		1.44	0.84–2.45	0.182
γ-GT >60 U/L	52	1.78	1.01–3.13	0.045*		1.75	1.14–2.69	0.011*
CEA >5 ng/mL	34	2.24	1.26–3.96	0.006*		1.85	1.17–2.92	0.008*
CA19-9 >37 U/mL	68	1.24	0.70–2.18	0.466		1.90	1.22–2.97	0.005*
Serum OPN/volume	62	0.53	0.29–0.94	0.030*		0.53	0.34–0.82	0.004*
Adjuvant TACE	19	1.21	0.59–2.49	0.609		1.08	0.60–1.96	0.792
Adjuvant chemotherapy	22	0.21	0.05–0.87	0.031*		0.85	0.47–1.54	0.583
Adjuvant radiotherapy	9	1.06	0.38–2.94	0.917		1.08	0.50–2.35	0.844

Analysis were performed using Cox proportional hazards model. *, P<0.05 by the Cox regression test. HBsAg, hepatitis B surface antigen; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl-transferase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; TACE, transhepatic arterial chemotherapy and embolization. OS, overall survival; DFS, disease-free survival; ICC, intrahepatic cholangiocarcinoma.